Tolcapone in obsessive-compulsive disorder: a randomized double-blind placebo-controlled crossover trial

aUniversity of Chicago, Department of Psychiatry and Behavioral Neuroscience, Chicago, Illinois, USA

bDepartment of Psychiatry, University of Cambridge, Cambridge, UK

cDepartment of Psychiatry, Faculty of Medicine, University of Southampton; and Southern Health NHS Foundation Trust, Southampton, UK.

Received 1 March 2021 Accepted 26 April 2021

ClinicalTrials.gov Identifier: NCT03348930

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.intclinpsychopharm.com

Correspondence to Jon E. Grant, JD, MD, MPH, Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Pritzker School of Medicine, 5841 S. Maryland Avenue, MC-3077, Chicago, IL 60637, USA, Tel: +773 834 1325; e-mail: [email protected]

留言 (0)

沒有登入
gif